시장보고서
상품코드
1673593

면역글로불린 시장 규모, 점유율, 성장 분석 : 적응증별, 제형별, 투여 경로별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)

Immunoglobulin Market Size, Share, and Growth Analysis, By Indication (Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID)), By Form (Liquid, Lyophilized), By Route of Administration, By End-User, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 219 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

면역글로불린 시장 규모는 2023년 164억 달러, 2024년 175억 2,000만 달러에서 2032년에는 296억 5,000만 달러로 성장하고, 예측 기간(2025-2032년) 동안 6.8%의 연평균 복합 성장률(CAGR)을 보일 것으로 예상됩니다.

세계 면역글로불린 시장은 면역 질환의 유병률 증가와 진단 및 치료 기술의 발전에 힘입어 큰 폭의 성장이 예상됩니다. 규제 상황과 의료비 지출 증가가 이러한 성장을 더욱 촉진하고 있습니다. 기술 혁신과 연구개발에 대한 투자 확대로 면역글로불린 치료의 품질과 효능이 향상되고 있습니다. 또한, 아시아태평양과 라틴아메리카를 중심으로 한 신흥 시장은 큰 성장 기회를 제공합니다. 이러한 통찰력은 면역글로불린 시장의 유망한 전망을 시사하며, 업계 이해관계자들에게 이러한 중요한 치료법에 대한 증가하는 수요를 충족시키기 위해 혁신을 우선시하고, 생산 능력을 확대하며, 시장 침투 전략을 모색할 것을 촉구하고 있습니다.

목차

서론

  • 조사 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차와 1차 데이터 방법
  • 시장 규모 예측
  • 시장 전제조건과 제한

주요 요약

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porter의 Five Forces 분석

주요 시장 인사이트

  • 중요 성공 요인
  • 경쟁 정도
  • 주요 투자 기회
  • 시장 생태계
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석
  • 규제 상황
  • 사례 연구
  • 특허 분석

면역글로불린 시장 규모 : 적응증별&CAGR(2025-2032년)

  • 시장 개요
  • 원발성 면역 결핍증(PI)
  • 2차 면역 결핍증(SID)
  • 만성 염증성 탈골수성 다발신경염(CIDP)
  • 길랑 바레 증후군
  • 면역 혈소판 감소성 자반병(ITP)
  • 다소성 운동신경 장애(MMN)
  • 기타

면역글로불린 시장 규모 : 제형별&CAGR(2025-2032년)

  • 시장 개요
  • 액체
  • 동결건조

면역글로불린 시장 규모 : 투여 경로별&CAGR(2025-2032년)

  • 시장 개요
  • 정맥내
  • 피하

면역글로불린 시장 규모 : 최종사용자별&CAGR(2025-2032년)

  • 시장 개요
  • 병원
  • 클리닉
  • 홈케어
  • 기타

면역글로불린 시장 규모&CAGR(2025-2032년)

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 주요 5개사 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 최근 시장 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업 개요
    • 기업 상세
    • 제품 포트폴리오 분석
    • 기업 부문별 점유율 분석
    • 전년대비 매출 비교(2022-2024년)

주요 기업 개요

  • Grifols(Spain)
  • CSL Limited(Australia)
  • Octapharma(Switzerland)
  • Kedrion Biopharma(Italy)
  • Biotest AG(Germany)
  • LFB Group(France)
  • Shanghai RAAS Blood Products(China)
  • China Biologic Products Holdings(China)
  • Baxter International Inc.(USA)
  • Takeda Pharmaceutical Company(Japan)
  • Sanquin(Netherlands)
  • Bio Products Laboratory(UK)
  • Emergent BioSolutions(USA)
  • ADMA Biologics(USA)
  • Kamada Ltd.(Israel)
  • Green Cross Corporation(South Korea)
  • SK Plasma(South Korea)
  • Hualan Biological Engineering Inc.(China)
  • Beijing Tiantan Biological Products(China)
  • Shire Plc(UK)

결론과 제안

LSH 25.04.11

Immunoglobulin Market size was valued at USD 16.4 billion in 2023 and is poised to grow from USD 17.52 billion in 2024 to USD 29.65 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global Immunoglobulin market is poised for considerable growth, fueled by the rising incidence of immunological disorders and advancements in diagnostic and therapeutic techniques. A supportive regulatory landscape and increasing healthcare expenditures further bolster this expansion. Innovations and heightened investment in research and development are enhancing the quality and effectiveness of Immunoglobulin therapies. Additionally, emerging markets, notably in the Asia-Pacific and Latin America regions, offer substantial opportunities for growth. These insights suggest a promising outlook for the Immunoglobulin market, encouraging industry stakeholders to prioritize innovation, scale up capacities, and explore market penetration strategies to satisfy the growing demand for these vital therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunoglobulin Market Segments Analysis

Global Immunoglobulin Market is segmented by Indication, Form, Route of Administration, End-User and region. Based on Indication, the market is segmented into Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain Barre Syndrome, Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN) and Others. Based on Form, the market is segmented into Liquid and Lyophilized. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, Intramuscular. Based on End-User, the market is segmented into Hospitals, Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Immunoglobulin Market

A significant driver of the global Immunoglobulin market is the rising incidence of immunological disorders. Immunoglobulins are essential for treating a variety of conditions, including primary immunodeficiencies, autoimmune diseases, and infectious diseases. The growing prevalence of these disorders, enhanced by better diagnostic methods and increased awareness, is driving the demand for Immunoglobulin therapies. Contributing factors include genetic susceptibility, environmental influences, and lifestyle shifts that lead to a higher occurrence of immunological issues worldwide. Moreover, improvements in healthcare infrastructure, greater access to medical services, and increasing healthcare spending are also pivotal in propelling the market's expansion.

Restraints in the Immunoglobulin Market

A major constraint faced by the global Immunoglobulin market is the steep cost associated with Immunoglobulin therapies. The intricate processes required for the production, purification, and storage of these therapies contribute to elevated manufacturing expenses, which in turn lead to higher prices for patients and healthcare systems. This financial barrier is particularly pronounced in developing nations where healthcare resources are limited and affordability is a critical concern. Additionally, reimbursement challenges and restricted insurance coverage further exacerbate the financial strain on individuals seeking these therapies. Consequently, it is vital to explore strategies aimed at minimizing production costs, fostering market competition, and enhancing the availability of affordable Immunoglobulin treatments to improve patient access and care.

Market Trends of the Immunoglobulin Market

The global Immunoglobulin market is witnessing a prominent trend characterized by a surge in the adoption of intravenous immunoglobulin (IVIG) therapy. This therapy, crucial for patients with immunodeficiency disorders, autoimmune diseases, and specific neurological conditions, has gained traction due to its proven efficacy and the heightened awareness of its therapeutic benefits among healthcare professionals and patients alike. Innovations in production technologies, enhanced product safety standards, and the broadening scope of IVIG indications are fueling this adoption. Concurrently, the rising incidence of immunological disorders and an aging population are further propelling the demand for Immunoglobulin products, solidifying IVIG therapy's pivotal role in modern medicine.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Landscape
  • Case Studies
  • Patent Analysis

Global Immunoglobulin Market Size by Indication & CAGR (2025-2032)

  • Market Overview
  • Primary Immunodeficiency (PI)
  • Secondary Immunodeficiency (SID)
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Guillain Barre Syndrome
  • Immune Thrombocytopenic Purpura (ITP)
  • Multifocal Motor Neuropathy (MMN)
  • Others

Global Immunoglobulin Market Size by Form & CAGR (2025-2032)

  • Market Overview
  • Liquid
  • Lyophilized

Global Immunoglobulin Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Intravenous
  • Subcutaneous

Global Immunoglobulin Market Size by End-User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Clinics
  • Homecare
  • Others

Global Immunoglobulin Market Size & CAGR (2025-2032)

  • North America (Indication, Form, Route of Administration, End-User)
    • US
    • Canada
  • Europe (Indication, Form, Route of Administration, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Indication, Form, Route of Administration, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Indication, Form, Route of Administration, End-User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Indication, Form, Route of Administration, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Grifols (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CSL Limited (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Octapharma (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kedrion Biopharma (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biotest AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LFB Group (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shanghai RAAS Blood Products (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • China Biologic Products Holdings (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanquin (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio Products Laboratory (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Emergent BioSolutions (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ADMA Biologics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kamada Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Green Cross Corporation (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SK Plasma (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hualan Biological Engineering Inc. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Beijing Tiantan Biological Products (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shire Plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제